logo
  Join        Login             Stock Quote

Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012

Tuesday, May 8, 2012 9:30 AM


Abstract scheduled for podium presentation also the subject of a 2012 Conquer Cancer Foundation of ASCO Merit Award

WORCESTER, Mass. and TORONTO, May 8, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that abstracts featuring the AE37 breast cancer vaccine clinical program of Generex wholly-owned subsidiary Antigen Express, Inc. will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (http://chicago2012.asco.org) taking place June 1-5, 2012 in Chicago, IL.

An abstract entitled "From bench to bedside: The use of the li-Key technology to improve helper peptides for clinical use in cancer vaccines" will be the subject of an oral presentation on Monday, June 4, 2012 at 5:30 pm CDT during the session on Developmental Therapeutics – Clinical Pharmacology and Immunotherapy.  This abstract was recognized with a 2012 Conquer Cancer Foundation of ASCO Merit Award bestowed by the Conquer Cancer Foundation of the American Society of Clinical Oncology and the 2012 Scientific Program Committee.  The merit award program was established to recognize high quality abstracts.

An abstract entitled "An assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized phase II trial" will be the subject of a poster presentation on Saturday, June 2, 2012 from 8 am – 12 pm CDT.

"The inclusion of these abstracts in this year's ASCO annual meeting is a reflection of both the quality and the maturity of the Antigen Express AE37 breast cancer vaccine clinical program," stated Mark Fletcher, Generex President & Chief Executive Officer.  "We look forward to updating the oncology community on our progress."  In December 2011 the Company announced positive interim results of the ongoing Phase II clinical trial of the vaccine.  The Company has previously announced its intention to organize an End-of-Phase II meeting with the U.S. Food & Drug Administration (FDA) and move into pivotal Phase III trials.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.


Advertisement
Advertisement



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.